Form 4: PAHC COO Larry Miller Granted 5,184 RSUs

Phibro Animal Health Corp's Chief Operating Officer, Larry Lee Miller, was granted 5,184 restricted stock units as part of his compensation.

Summary

• Larry Lee Miller, Chief Operating Officer of Phibro Animal Health Corp (PAHC), was granted 5,184 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs were granted on August 15, 2025, with a transaction price of $0.
• Following this transaction, Mr. Miller beneficially owns 35,184 shares of Class A Common Stock directly.
• The RSUs will vest in substantially equal installments on the first three anniversaries of August 1, 2025, contingent on Mr. Miller's continued employment.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation grant, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests, but does not indicate significant operational or financial news.

Positives

• Grant of restricted stock units aligns the Chief Operating Officer's interests with long-term shareholder value.
• The vesting schedule incentivizes continued employment and performance over a multi-year period.

Future Outlook

The granted restricted stock units are set to vest in substantially equal installments on the first three anniversaries of August 1, 2025, contingent on the Chief Operating Officer's continued employment.

Industry Context

This RSU grant is a standard component of executive compensation packages in the animal health and broader pharmaceutical industries, designed to retain key talent and align management incentives with long-term company performance.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as a form of equity compensation is a common practice across publicly traded companies, including those in the animal health sector like Zoetis Inc. (ZTS) or Elanco Animal Health Incorporated (ELAN).
• The vesting schedule over three years is typical for executive equity awards, comparable to practices at companies such as Merck & Co., Inc. (MRK) or Pfizer Inc. (PFE) for their executive compensation plans.
• The $0 price for RSUs is standard, as these are compensatory grants rather than stock purchases, aligning with industry benchmarks for non-qualified deferred compensation or performance-based awards.

Related Party Transactions

• The grant of 5,184 restricted stock units to Larry Lee Miller, the Chief Operating Officer, constitutes a transaction between the company and a key executive, which is a common form of related party compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Operating Officer's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Employees: The grant may signal stability in executive leadership and a commitment to performance-based incentives.

Next Steps

• The restricted stock units will vest in substantially equal installments on the first three anniversaries of August 1, 2025.
• Continued employment of the Chief Operating Officer is required for the vesting of the RSUs.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not contain information that would significantly alter the fundamental investment thesis for Phibro Animal Health Corp. While the RSU grant aligns management incentives, it is a standard practice and not indicative of new operational performance or strategic shifts that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Phibro Animal Health, PAHC, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Larry Lee Miller, Chief Operating Officer, Stock Grant